What prior-treatment criteria apply to radium-223 dichloride (Xofigo) for adults with metastatic castration-resistant prostate cancer?

Xofigo (radium-223 dichloride) is indicated for adults with metastatic castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases whose disease has progressed after at least two systemic treatment lines for mCRPC (excluding LHRH analogues), or who are ineligible for any available systemic mCRPC treatment.